SBIR/STTR Research Award

Study of Transcutaneous Auricular Neurostimulation as a Treatment for Alcohol Use Disorder

Award identifier ab69203b0864067e7283465f9b490a284158dc7784d4544242ddf4d9814a0144Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$305,545

Program and phase

STTR · Phase I

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SPARK BIOMEDICAL INC.
Proposal award date
2025-09-01
Contract end date
2026-08-31
UEI
KUGZUDSCWQK5
Solicitation number
PA23-233
Topic code
350

Research abstract

PROJECT SUMMARY/ABSTRACT Alcohol use disorder (AUD) is a major health problem in the United States, often attributed to factors impacting the mesolimbic and cortico-striatal systems in the brain. Currently, there is a pressing need for the development of both therapeutic interventions and effective biomarkers for alcohol withdrawal syndrome (AWS) and alcohol- related psychiatric symptoms. One promising non-pharmacological approach is transcutaneous auricular neurostimulation (tAN), a non- invasive neurostimulation technique that stimulates neurotransmitter systems. tAN combines vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Our study has shown that tAN is a safe and effective non-invasive treatment for reducing substance withdrawal symptoms, particularly those from opioids, suggesting its potential as a therapeutic tool for improving AWS. The aim is to lower a patient’s desire for alcohol use and lessen the chance of relapse. Furthermore, another promising avenue is the integration of neuroimaging with clinical outcomes, aiming to establish an fMRI-based objective biomarker for AUD. Incorporating tAN into this framework allows us to go beyond mere biomarker development, offering a unique and quantifiable therapeutic strategy. The proposed research endeavors to comprehensively investigate the efficacy of tAN as a treatment for AWS and the development of neuroimaging biomarkers in patients with AUD. This research initiative aims to provide a comprehensive clinical package, offering a valuable therapeutic tool. Ultimately, this work not only advances the application of tAN in clinical settings but also contributes significantly to the broader field of translational medical research.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2019–2025). Reported award amounts total $7,155,580. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.